Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Retrospective Multicenter Observational Study to Evaluate Safety and Effectiveness of Bevacizumab (Avastin) in Combination With Paclitaxel and Cisplatin/Carboplatin or Toptecan in Patients With Advanced Cervical Cancer

Trial Profile

Retrospective Multicenter Observational Study to Evaluate Safety and Effectiveness of Bevacizumab (Avastin) in Combination With Paclitaxel and Cisplatin/Carboplatin or Toptecan in Patients With Advanced Cervical Cancer

Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Mar 2018

At a glance

  • Drugs Bevacizumab (Primary) ; Carboplatin; Cisplatin; Paclitaxel; Topotecan
  • Indications Cervical cancer
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 28 Feb 2018 Status changed from recruiting to completed.
    • 29 Sep 2017 Planned End Date changed from 1 Sep 2017 to 20 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top